Novozymes Expands Partnership with Upperton

Combining Novozymes' IP and expertise around the albumin molecules with Upperton’s rP-conjugate albumin conjugation chemistry knowledge, enables the companies to design and implement the best chemical linking approach for their molecule.

Danish firm Novozymes Biopharma has expanded its partnership with UK-based research and development company, Upperton, to offer a new albumin conjugation solution.

By linking drugs to Novozymes’ new Recombumin Flex recombinant human albumin (rAlbumin), using conjugation, their pharmacokinetic and pharmacodynamic properties can be dramatically enhanced. As a result, manufacturers can benefit from tailoring and controlling the half-life of drugs to fit a patient’s medical needs.

According to Novozymes Biopharma, Upperton has demonstrated that proteins, peptides and small molecule APIs can be covalently attached to recombinant human albumin using a range of chemistries. Additionally, once drugs have been linked to the recombinant human albumin carrier, they exhibi